Solgo Biomedical (CEO Kim Il) announced on the 10th that it has signed an exclusive domestic sales contract for the cervical artificial disc Baguera®-C from Swiss implant manufacturer Spineart.
Spineart, a global implant manufacturing specialist, has been selling spinal implants in over 55 countries including the United States for the past 20 years. Baguera®-C is an artificial disc product competing with global medical device companies such as Medtronic, ZimVie, DePuy Synthes in the US, and Signus in Germany, and has been used in more than 50,000 artificial disc replacement surgeries worldwide.
Through this exclusive contract, Solgo Biomedical has laid the foundation for entering the domestic spinal artificial disc market and expanding its high value-added business by supplying the globally recognized high-quality and high value-added product Baguera®-C. A company official stated, “Baguera®-C is a product whose usability and quality have been proven in the global market through clinical trials,” adding, “This product has already obtained medical device certification from the Korean Ministry of Food and Drug Safety, and it is expected to capture more than 30% of the domestic artificial disc market share in a short period.”
The cervical artificial disc replaces the damaged disc by removing it and inserting a specially designed artificial disc to treat degenerative cervical disc disease. This product is a high-tech spinal implant that preserves the natural movement of the spinal segment and prevents degeneration of adjacent segments. Medical device approval requires high quality and sufficient clinical trials. Baguera®-C guarantees surgical simplicity with a low-profile design suitable for the patient’s body. It has been recognized for safety by demonstrating excellent surgical outcomes through numerous clinical trials.
Kim Il, CEO of Solgo Biomedical, said, “Gaining trust from doctors and patients is important to lead the domestic market,” and added, “Our company will do its best to increase market accessibility for this product and provide it to users in the best condition.”
Meanwhile, starting with this artificial disc product, Solgo Biomedical plans to continuously launch new products such as 3D printed cages, implant systems for spinal deformity surgery cases, and robotic surgery systems to target the domestic spinal market.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
